ReviewCurrent rheumatology reports2020
Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.
Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis.Seminars in arthritis and rheumatism · 2022Pooled it
- Assessment of the prevalence of neurological involvement in a pediatric cohort of children with lupus nephritis: retrospective multicenter study.Pediatric nephrology (Berlin, Germany) · 2026Article
- JAK Inhibition inJIMD reports · 2026Article
- A dual-pronged host-directed therapeutic targeting cyclophilin A and pathogenic interferon response abrogates virus-triggered pregnancy pathologies.Nature communications · 2026Article
- A novel stop-loss variant in ISG15 causes C-terminal dysfunction and impairs USP18-mediated negative feedback.Frontiers in immunology · 2026Article
- Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.Current rheumatology reports · 2025Review
- Neonatal lupus erythematosus presenting with congenital heart block: clinical characteristics and follow-up.Clinical rheumatology · 2025Article
- Interferon and immunity: the role of microRNA in viral evasion strategies.Frontiers in immunology · 2025Review
- COPA Syndrome-From Pathogenesis to Treatment.Diagnostics (Basel, Switzerland) · 2024Review
- JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases.Journal of clinical medicine · 2023Review
- Type I Interferonopathies in Childhood.Balkan medical journal · 2023Article
- Case report: Durable response to ruxolitinib in a child withFrontiers in pediatrics · 2023Article
- Novel heterozygousFrontiers in immunology · 2023Article
- Interferon in systemic lupus erythematosus-A halfway between monogenic autoinflammatory and autoimmune disease.Heliyon · 2022Review
- Precision medicine: The use of tailored therapy in primary immunodeficiencies.Frontiers in immunology · 2022Review
- Simultaneous Onset of Pediatric Systemic Lupus Erythematosus in Twin Brothers: Case Report.Frontiers in pediatrics · 2022Article
- DNA hypomethylation leads to cGAS-induced autoinflammation in the epidermis.The EMBO journal · 2021Article
- Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases.Nature reviews. Rheumatology · 2021Review
- Ruxolitinib in Aicardi-Goutières syndrome.Metabolic brain disease · 2021Article
- Crosstalk between Interleukin-1β and Type I Interferons Signaling in Autoinflammatory Diseases.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewType I interferonopathies are monogenic autoinflammatory diseases induced by constitutive activation of type I interferon. Here, we provide an overview of these diseases and describe underlying molecular pathways, related phenotypes, suggestive clinical signs and investigations for helping diagnosis process and therapeutic management. RECENT
findingsRecent genetic and functional discoveries have enabled deciphering mechanisms involved in the pathogenesis of the type I interferonopathies and considering promising targeted treatments, such as JAK inhibitors, both for monogenic and multifactorial interferon-related diseases. The concept of the type I interferonopathies rests on the assumption that some diseases arise from a disturbance of interferon signalling pathway. In the presence of suggestive clinical signs (especially involving the central nervous system and the skin), a consistent positive type I interferon assessment is a further point in favour of genetic investigations in patients. This review also highlights the potential value of targeted therapeutics that should improve features of type I interferonopathies, thereby providing a validation of the underlying hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.